Literature DB >> 27111229

Public T cell receptors confer high-avidity CD4 responses to HIV controllers.

Daniela Benati, Moran Galperin, Olivier Lambotte, Stéphanie Gras, Annick Lim, Madhura Mukhopadhyay, Alexandre Nouël, Kristy-Anne Campbell, Brigitte Lemercier, Mathieu Claireaux, Samia Hendou, Pierre Lechat, Pierre de Truchis, Faroudy Boufassa, Jamie Rossjohn, Jean-François Delfraissy, Fernando Arenzana-Seisdedos, Lisa A Chakrabarti.   

Abstract

The rare patients who are able to spontaneously control HIV replication in the absence of therapy show signs of a particularly efficient cellular immune response. To identify the molecular determinants that underlie this response, we characterized the T cell receptor (TCR) repertoire directed at Gag293, the most immunoprevalent CD4 epitope in the HIV-1 capsid. HIV controllers from the ANRS CODEX cohort showed a highly skewed TCR repertoire that was characterized by a predominance of TRAV24 and TRBV2 variable genes, shared CDR3 motifs, and a high frequency of public clonotypes. The most prevalent public clonotypes generated TCRs with affinities at the higher end of values reported for naturally occurring TCRs. The high-affinity Gag293-specific TCRs were cross-restricted by up to 5 distinct HLA-DR alleles, accounting for the expression of these TCRs in HIV controllers of diverse genetic backgrounds. Transfer of these TCRs to healthy donor CD4+ T cells conferred high antigen sensitivity and polyfunctionality, thus recapitulating key features of the controller CD4 response. Transfer of a high-affinity Gag293-specific TCR also redirected CD8+ T cells to target HIV-1 capsid via nonconventional MHC II restriction. Together, these findings indicate that TCR clonotypes with superior functions are associated with HIV control. Amplification or transfer of such clonotypes may contribute to immunotherapeutic approaches aiming at a functional HIV cure.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27111229      PMCID: PMC4887161          DOI: 10.1172/JCI83792

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS.

Authors:  Eltaf Alamyar; Patrice Duroux; Marie-Paule Lefranc; Véronique Giudicelli
Journal:  Methods Mol Biol       Date:  2012

2.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory.

Authors:  Matthew A Williams; Eugene V Ravkov; Michael J Bevan
Journal:  Immunity       Date:  2008-03-20       Impact factor: 31.745

4.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Authors:  Olivier Lambotte; Faroudy Boufassa; Yoann Madec; Ahn Nguyen; Cécile Goujard; Laurence Meyer; Christine Rouzioux; Alain Venet; Jean-François Delfraissy
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

5.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Authors:  Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

Review 7.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

8.  Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection.

Authors:  Geraldine M A Gillespie; Guillaume Stewart-Jones; Jaya Rengasamy; Tara Beattie; Job J Bwayo; Francis A Plummer; Rupert Kaul; Andrew J McMichael; Philippa Easterbrook; Tao Dong; E Yvonne Jones; Sarah L Rowland-Jones
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

9.  A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells.

Authors:  Kristin Ladell; Masao Hashimoto; Maria Candela Iglesias; Pascal G Wilmann; James E McLaren; Stéphanie Gras; Takayuki Chikata; Nozomi Kuse; Solène Fastenackels; Emma Gostick; John S Bridgeman; Vanessa Venturi; Zaïna Aït Arkoub; Henri Agut; David J van Bockel; Jorge R Almeida; Daniel C Douek; Laurence Meyer; Alain Venet; Masafumi Takiguchi; Jamie Rossjohn; David A Price; Victor Appay
Journal:  Immunity       Date:  2013-03-21       Impact factor: 31.745

10.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

Authors:  Jorge R Almeida; David A Price; Laura Papagno; Zaïna Aït Arkoub; Delphine Sauce; Ethan Bornstein; Tedi E Asher; Assia Samri; Aurélie Schnuriger; Ioannis Theodorou; Dominique Costagliola; Christine Rouzioux; Henri Agut; Anne-Geneviève Marcelin; Daniel Douek; Brigitte Autran; Victor Appay
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

View more
  29 in total

1.  Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Authors:  Kenji Sugata; Yukiko Matsunaga; Yuki Yamashita; Munehide Nakatsugawa; Tingxi Guo; Levon Halabelian; Yota Ohashi; Kayoko Saso; Muhammed A Rahman; Mark Anczurowski; Chung-Hsi Wang; Kenji Murata; Hiroshi Saijo; Yuki Kagoya; Dalam Ly; Brian D Burt; Marcus O Butler; Tak W Mak; Naoto Hirano
Journal:  Nat Biotechnol       Date:  2021-03-01       Impact factor: 54.908

2.  T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable.

Authors:  Alok V Joglekar; Zhe Liu; Jeffrey K Weber; Yong Ouyang; John D Jeppson; Won Jun Noh; Pedro A Lamothe-Molina; Huabiao Chen; Seung-Gu Kang; Michael T Bethune; Ruhong Zhou; Bruce D Walker; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-07       Impact factor: 11.205

Review 3.  Dendritic Cell Immune Responses in HIV-1 Controllers.

Authors:  Enrique Martin-Gayo; Xu G Yu
Journal:  Curr HIV/AIDS Rep       Date:  2017-02       Impact factor: 5.071

4.  T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Authors:  Michael D Keller; Sam Darko; Haili Lang; Amy Ransier; Christopher A Lazarski; Yunfei Wang; Patrick J Hanley; Blachy J Davila; Jennifer R Heimall; Richard F Ambinder; A John Barrett; Cliona M Rooney; Helen E Heslop; Daniel C Douek; Catherine M Bollard
Journal:  Br J Haematol       Date:  2019-06-20       Impact factor: 6.998

5.  MHC Class II Tetramer Labeling of Human Primary CD4+ T Cells from HIV Infected Patients.

Authors:  Moran Galperin; Daniela Benati; Mathieu Claireaux; Madhura Mukhopadhyay; Lisa A Chakrabarti
Journal:  Bio Protoc       Date:  2017-03-20

6.  Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells.

Authors:  Hamza Loucif; Xavier Dagenais-Lussier; Daina Avizonis; Luc Choinière; Cherifa Beji; Léna Cassin; Jean-Pierre Routy; Jörg H Fritz; David Olagnier; Julien van Grevenynghe
Journal:  Autophagy       Date:  2021-10-06       Impact factor: 13.391

7.  DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Authors:  Madhura Mukhopadhyay; Moran Galperin; Mandar Patgaonkar; Sandhya Vasan; David D Ho; Alexandre Nouël; Mathieu Claireaux; Daniela Benati; Olivier Lambotte; Yaoxing Huang; Lisa A Chakrabarti
Journal:  J Immunol       Date:  2017-10-09       Impact factor: 5.422

8.  The discriminatory power of the T cell receptor.

Authors:  Johannes Pettmann; Anna Huhn; Enas Abu Shah; Mikhail A Kutuzov; Daniel B Wilson; Michael L Dustin; Simon J Davis; P Anton van der Merwe; Omer Dushek
Journal:  Elife       Date:  2021-05-25       Impact factor: 8.140

9.  Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients.

Authors:  Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Jeremy Chase Crawford; Liyen Loh; Sneha Sant; Ludivine Grzelak; Emma K Allen; Tim Brahm; E Bridie Clemens; Maria Auladell; Luca Hensen; Zhongfang Wang; Simone Nüssing; Xiaoxiao Jia; Patrick Günther; Adam K Wheatley; Stephen J Kent; Malet Aban; Yi-Mo Deng; Karen L Laurie; Aeron C Hurt; Stephanie Gras; Jamie Rossjohn; Jane Crowe; Jianqing Xu; David Jackson; Lorena E Brown; Nicole La Gruta; Weisan Chen; Peter C Doherty; Stephen J Turner; Tom C Kotsimbos; Paul G Thomas; Allen C Cheng; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

10.  Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.

Authors:  Léo Plaçais; Faroudy Boufassa; Camille Lécuroux; Elise Gardiennet; Véronique Avettand-Fenoel; Asier Saez-Cirion; Olivier Lambotte; Nicolas Noël
Journal:  EClinicalMedicine       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.